Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Endocannabinoids and cannabinoid type 1 (CB1) receptors are implicated in animal models of PTSD.
• The specific role of these systems in human PTSD remains understudied.

Purpose of the Study:

• To investigate in vivo CB1 receptor availability and endocannabinoid levels in individuals with PTSD.
• To explore the relationship between these biomarkers and PTSD diagnosis.

Main Methods:

• Positron emission tomography (PET) with [(11)C]OMAR (a CB1 radioligand) was used to measure CB1 receptor availability (VT).
• Participants included individuals with PTSD (N=25), trauma-exposed controls (TC, N=12), and healthy controls (HC, N=23).
• Peripheral levels of anandamide, other endocannabinoids, and cortisol were assessed.

Main Results:

• Elevated brain-wide [(11)C]OMAR VT values were observed in the PTSD group compared to HC and TC groups (P=0.001).
• Anandamide concentrations were significantly reduced in the PTSD group relative to both control groups (P<0.001).
• A combination of OMAR VT, anandamide, and cortisol levels achieved nearly 85% accuracy in classifying PTSD cases.

Conclusions:

• Abnormal CB1 receptor-mediated anandamide signaling is implicated in the etiology of PTSD.
• These findings suggest a promising neurobiological model for developing novel pharmacotherapies for PTSD.